Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Operations Officer | January 04, 2023 | January 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 04, 2023 · Filed January 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,515 |
Ending reported balance
After 2023-01-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-01-04 · Sale · Disposed 6,381 · Balance 268,918 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Row 2 · 2023-01-04 · Sale · Disposed 11 · Balance 268,907 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Row 3 · 2023-01-05 · Sale · Disposed 3,372 · Balance 265,535 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Row 4 · 2023-01-05 · Sale · Disposed 20 · Balance 265,515 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 6, 2023 22:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 20 | $1.11 | $22.21 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 4 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,515 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,372 | $1.13 | $3,808.00 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,535 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 11 | $1.14 | $12.54 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,907 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 6,381 | $1.13 | $7,234.14 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,918 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000019 · wf-form4_167286967765220.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2033-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000019 · wf-form4_167286967765220.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,299 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,416 | $3.09 | $10,541.43 |
DisclosureSEC source: 0001453687-22-000032 · wf-form4_164159027075368.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,299 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.99 to $3.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 340,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000019 · wf-form4_164141842250529.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2032-01-02 F2 · derivative.exercise_date: This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:33 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 72,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000019 · wf-form4_164141842250529.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,715 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,370 | $2.99 | $13,052.75 |
DisclosureSEC source: 0001453687-21-000184 · wf-form4_163952016550751.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,715 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.94 to $3.0201. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000174 · wf-form4_163917400856591.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,085 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the "Performance RSUs"), which were earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. The compensation committee of the board of directors of the Issuer has determined that the second of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on December 8, 2021. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 22:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,892 | $4.39 | $17,085.88 |
DisclosureSEC source: 0001453687-21-000142 · wf-form4_163433562992987.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,335 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.35 to $4.475. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:26 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000133 · wf-form4_163346554315584.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,227 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the "Performance RSUs"), which may be earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. Any Performance RSUs will generally vest in two equal installments upon the dates of achievement of each of the two performance conditions, subject to continued employment, so long as each performance condition is met before December 31, 2021. The compensation committee of the board of directors of the Issuer has determined that the first of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on October 1, 2021. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 21:33 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 15,128 | $4.45 | $67,312.04 |
DisclosureSEC source: 0001453687-21-000033 · wf-form4_161618956509768.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,477 F1 · kind: Shares were sold to cover costs of exercising expiring employee stock options on February 11, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.425 to $4.48. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:10 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 44,871 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001453687-21-000020 · wf-form4_161351699826212.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,871 shares Expires 2021-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:10 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 44,871 | $0.63 | $28,268.73 |
DisclosureSEC source: 0001453687-21-000020 · wf-form4_161351699826212.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person has elected to exercise and hold the shares at this time in advance of the option's expiration. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001453687-21-000016 · wf-form4_160996977743505.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2031-01-03 F2 · derivative.exercise_date: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000016 · wf-form4_160996977743505.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,734 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:11 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001104659-20-081209 · a4.xml · derivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO & SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: This option will vest as to 25% on July 1, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 22:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,128 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001453687-20-000019 · wf-form4_157964528662973.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,128 shares Expires 2020-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 22:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 5,128 | $0.47 | $2,410.16 |
DisclosureSEC source: 0001453687-20-000019 · wf-form4_157964528662973.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000011 · wf-form4_157835923174735.xml · derivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 20:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001453687-19-000146 · wf-form4_157065237102298.xml · derivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-10-06 F1 · derivative.exercise_date: This option shall vest as to 50% of the shares on October 7, 2020, and the remaining 50% of the shares on October 7, 2021. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 20:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001453687-19-000084 · wf-form4_156408571299475.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 20:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,000 | $0.47 | $4,700.00 |
DisclosureSEC source: 0001453687-19-000084 · wf-form4_156408571299475.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:23 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $2.60 Strike: $2.60 | $260,000.00 |
DisclosureSEC source: 0001453687-19-000015 · wf-form4_154698258841554.xml · derivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-06 F1 · derivative.exercise_date: This option will vest as to 25% on January 7, 2020. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 23:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000681 · doc4_5476.xml · derivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:46 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $19.33 | $0.00 |
DisclosureSEC source: 0001638599-17-000702 · doc4_4844.xml · derivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO & Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,959 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001638599-17-000685 · doc4_4832.xml · derivative · entry 4 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126 Underlying: Common Stock · 5,959 shares Expires 2023-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 5,859 | $19.09 | $111,832.49 |
DisclosureSEC source: 0001638599-17-000685 · doc4_4832.xml · nonDerivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,606 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.605 to $19.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 100 | $19.74 | $1,974.00 |
DisclosureSEC source: 0001638599-17-000685 · doc4_4832.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,465 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 to $19.76, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 5,959 | $2.77 | $16,506.43 |
DisclosureSEC source: 0001638599-17-000685 · doc4_4832.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:12 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,512 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001638599-17-000626 · doc4_4803.xml · derivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,512 shares Expires 2019-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:12 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 20,512 | $17.00 | $348,640.41 |
DisclosureSEC source: 0001638599-17-000626 · doc4_4803.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,606 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.95 to $17.10, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:12 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 20,512 | $0.47 | $9,640.64 |
DisclosureSEC source: 0001638599-17-000626 · doc4_4803.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R*D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jul 10, 2017 20:19 UTC Amendment | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,512 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001638599-17-000690 · doc4a_4836.xml · derivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,512 shares Expires 2019-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 19, 2017, the reporting person filed a Form 4 reporting the June 15, 2017 exercise and sale of 20,512 shares of common stock pursuant to a 10b5-1 plan. The reporting person's broker subsequently acknowledged that 10,000 of such 20,512 shares were erroneously exercised and sold by the broker. The exercise and sale of the 10,000 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in their entirety, the transactions reported in the June 19, 2017 Form 4. F4 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| June 15, 2017 Filed Jul 10, 2017 20:19 UTC Amendment | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 10,512 | $17.04 | $179,141.30 |
DisclosureSEC source: 0001638599-17-000690 · doc4a_4836.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,606 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016. F1 · shares: On June 19, 2017, the reporting person filed a Form 4 reporting the June 15, 2017 exercise and sale of 20,512 shares of common stock pursuant to a 10b5-1 plan. The reporting person's broker subsequently acknowledged that 10,000 of such 20,512 shares were erroneously exercised and sold by the broker. The exercise and sale of the 10,000 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in their entirety, the transactions reported in the June 19, 2017 Form 4. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.10, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| June 15, 2017 Filed Jul 10, 2017 20:19 UTC Amendment | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,512 | $0.47 | $4,940.64 |
DisclosureSEC source: 0001638599-17-000690 · doc4a_4836.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO and SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 19, 2017, the reporting person filed a Form 4 reporting the June 15, 2017 exercise and sale of 20,512 shares of common stock pursuant to a 10b5-1 plan. The reporting person's broker subsequently acknowledged that 10,000 of such 20,512 shares were erroneously exercised and sold by the broker. The exercise and sale of the 10,000 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in their entirety, the transactions reported in the June 19, 2017 Form 4. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 21:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,205 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001104659-17-024214 · a4.xml · derivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,205 shares Expires 2018-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 21:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 13,205 | $13.95 | $184,209.75 |
DisclosureSEC source: 0001104659-17-024214 · a4.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,606 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 21, 2016. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 21:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 13,205 | $0.39 | $5,149.95 |
DisclosureSEC source: 0001104659-17-024214 · a4.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2017 Filed Jan 30, 2017 21:54 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001104659-17-004977 · a4.xml · derivative · entry 4 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,205 Underlying: Common Stock · 15,000 shares Expires 2018-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| January 23, 2017 Filed Jan 30, 2017 21:54 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,890 | $14.17 | $55,121.30 |
DisclosureSEC source: 0001104659-17-004977 · a4.xml · nonDerivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,606 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $15.00, inclusive. Read SEC document |
| January 23, 2017 Filed Jan 30, 2017 21:54 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 11,110 | $13.95 | $154,984.50 |
DisclosureSEC source: 0001104659-17-004977 · a4.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,496 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.00, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4. Read SEC document |
| January 23, 2017 Filed Jan 30, 2017 21:54 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 15,000 | $0.39 | $5,850.00 |
DisclosureSEC source: 0001104659-17-004977 · a4.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · COO AND SVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.